HRP20090495T1 - Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom - Google Patents
Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom Download PDFInfo
- Publication number
- HRP20090495T1 HRP20090495T1 HR20090495T HRP20090495T HRP20090495T1 HR P20090495 T1 HRP20090495 T1 HR P20090495T1 HR 20090495 T HR20090495 T HR 20090495T HR P20090495 T HRP20090495 T HR P20090495T HR P20090495 T1 HRP20090495 T1 HR P20090495T1
- Authority
- HR
- Croatia
- Prior art keywords
- imidazo
- pyrazin
- image
- 10alkyl
- amino
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 48
- 125000001424 substituent group Chemical group 0.000 claims abstract 37
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract 24
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 22
- 150000003839 salts Chemical class 0.000 claims abstract 15
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims abstract 11
- 125000003118 aryl group Chemical group 0.000 claims abstract 9
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 6
- 125000004475 heteroaralkyl group Chemical group 0.000 claims abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract 4
- 125000005843 halogen group Chemical group 0.000 claims 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims 24
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 24
- 102000001253 Protein Kinase Human genes 0.000 claims 11
- 108060006633 protein kinase Proteins 0.000 claims 11
- 230000000694 effects Effects 0.000 claims 9
- -1 C2-10alkynyl Chemical group 0.000 claims 8
- 230000001404 mediated effect Effects 0.000 claims 7
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 4
- FUGZYLOFWXVFQU-UHFFFAOYSA-N 3-[3-(azetidin-1-ylmethyl)cyclobutyl]-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CC(CN3CCC3)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=C1 FUGZYLOFWXVFQU-UHFFFAOYSA-N 0.000 claims 4
- CRXFZICQPIJJRJ-UHFFFAOYSA-N 3-[4-(aminomethyl)cyclohexyl]-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C1CC(CN)CCC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N CRXFZICQPIJJRJ-UHFFFAOYSA-N 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QNQAPXGKMZTEPB-UHFFFAOYSA-N 3-cyclobutyl-1-(2-phenylquinolin-7-yl)-2,3-dihydroimidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CCC2)NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=C1 QNQAPXGKMZTEPB-UHFFFAOYSA-N 0.000 claims 3
- AWARRGOPBGTLFG-MXVIHJGJSA-N C1C[C@@H](C(=O)N)CC[C@@H]1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N Chemical compound C1C[C@@H](C(=O)N)CC[C@@H]1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N AWARRGOPBGTLFG-MXVIHJGJSA-N 0.000 claims 3
- LJWGLPMHPKZOPY-MEMLXQNLSA-N C1C[C@@H](C(=O)NC)CC[C@@H]1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N Chemical compound C1C[C@@H](C(=O)NC)CC[C@@H]1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N LJWGLPMHPKZOPY-MEMLXQNLSA-N 0.000 claims 3
- VNDZFEOMLUNBNZ-MXVIHJGJSA-N C=12C(N)=NC=CN2C([C@@H]2CC[C@H](CC2)C(O)=O)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=C1 Chemical compound C=12C(N)=NC=CN2C([C@@H]2CC[C@H](CC2)C(O)=O)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=C1 VNDZFEOMLUNBNZ-MXVIHJGJSA-N 0.000 claims 3
- SWCIISDMFBNTHC-RZFKFIIISA-N Nc1nccn2c(nc(-c3ccc4ccc(nc4c3)-c3ccccc3)c12)[C@H]1CC[C@H](CN2C(=O)c3ccccc3C2=O)CC1 Chemical compound Nc1nccn2c(nc(-c3ccc4ccc(nc4c3)-c3ccccc3)c12)[C@H]1CC[C@H](CN2C(=O)c3ccccc3C2=O)CC1 SWCIISDMFBNTHC-RZFKFIIISA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000025865 Ulcer Diseases 0.000 claims 3
- MEBFFPWZDJFILV-UHFFFAOYSA-N [3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutyl]methanol Chemical compound C=12C(N)=NC=CN2C(C2CC(CO)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=C1 MEBFFPWZDJFILV-UHFFFAOYSA-N 0.000 claims 3
- KQLFRRPQNLZQFD-UHFFFAOYSA-N [4-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexyl]methanol Chemical compound C=12C(N)=NC=CN2C(C2CCC(CO)CC2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=C1 KQLFRRPQNLZQFD-UHFFFAOYSA-N 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- PABMBMQQWJOHIS-UHFFFAOYSA-N methyl 4-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxylate Chemical compound C1CC(C(=O)OC)CCC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N PABMBMQQWJOHIS-UHFFFAOYSA-N 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 231100000397 ulcer Toxicity 0.000 claims 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 2
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- ZNJRINDKQVUSQJ-UHFFFAOYSA-N 1-(2-phenylquinolin-7-yl)-3-propan-2-ylimidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C(C)C)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=C1 ZNJRINDKQVUSQJ-UHFFFAOYSA-N 0.000 claims 1
- JZMFTFDSJSFVTH-UHFFFAOYSA-N 1-(6-chloro-2-phenoxyquinolin-7-yl)-3-[3-[(dimethylamino)methyl]cyclobutyl]imidazo[1,5-a]pyrazin-8-amine Chemical compound C1C(CN(C)C)CC1C1=NC(C=2C(=CC3=CC=C(OC=4C=CC=CC=4)N=C3C=2)Cl)=C2N1C=CN=C2N JZMFTFDSJSFVTH-UHFFFAOYSA-N 0.000 claims 1
- FTNNJHIGEKILDE-UHFFFAOYSA-N 1-(6-chloro-2-phenoxyquinolin-7-yl)-3-cyclobutylimidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CCC2)=NC=1C(C(=CC1=CC=2)Cl)=CC1=NC=2OC1=CC=CC=C1 FTNNJHIGEKILDE-UHFFFAOYSA-N 0.000 claims 1
- XIQPRISBXRBPMP-UHFFFAOYSA-N 1-(6-chloro-2-phenylquinolin-7-yl)-3-[3-(2-methoxyethoxy)cyclobutyl]imidazo[1,5-a]pyrazin-8-amine Chemical compound C1C(OCCOC)CC1C1=NC(C=2C(=CC3=CC=C(N=C3C=2)C=2C=CC=CC=2)Cl)=C2N1C=CN=C2N XIQPRISBXRBPMP-UHFFFAOYSA-N 0.000 claims 1
- NPJOPWWUNCTQSY-UHFFFAOYSA-N 1-(6-chloro-2-phenylquinolin-7-yl)-3-[3-[(dimethylamino)methyl]cyclobutyl]imidazo[1,5-a]pyrazin-8-amine Chemical compound C1C(CN(C)C)CC1C1=NC(C=2C(=CC3=CC=C(N=C3C=2)C=2C=CC=CC=2)Cl)=C2N1C=CN=C2N NPJOPWWUNCTQSY-UHFFFAOYSA-N 0.000 claims 1
- IGWCMCHNENNYMS-UHFFFAOYSA-N 1-(6-chloro-2-phenylquinolin-7-yl)-3-cyclobutylimidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CCC2)=NC=1C(C(=CC1=CC=2)Cl)=CC1=NC=2C1=CC=CC=C1 IGWCMCHNENNYMS-UHFFFAOYSA-N 0.000 claims 1
- CTTWBPHWZRHMJY-UHFFFAOYSA-N 1-(6-chloro-2-pyridin-2-ylquinolin-7-yl)-3-[3-[(dimethylamino)methyl]cyclobutyl]imidazo[1,5-a]pyrazin-8-amine Chemical compound C1C(CN(C)C)CC1C1=NC(C=2C(=CC3=CC=C(N=C3C=2)C=2N=CC=CC=2)Cl)=C2N1C=CN=C2N CTTWBPHWZRHMJY-UHFFFAOYSA-N 0.000 claims 1
- QOEGQGDHIOECBA-UHFFFAOYSA-N 1-(6-chloro-2-pyridin-2-ylquinolin-7-yl)-3-cyclobutylimidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CCC2)=NC=1C(C(=CC1=CC=2)Cl)=CC1=NC=2C1=CC=CC=N1 QOEGQGDHIOECBA-UHFFFAOYSA-N 0.000 claims 1
- JSTPUNDUDLHYSG-UHFFFAOYSA-N 1-(6-chloro-2-thiophen-2-ylquinolin-7-yl)-3-[3-[(dimethylamino)methyl]cyclobutyl]imidazo[1,5-a]pyrazin-8-amine Chemical compound C1C(CN(C)C)CC1C1=NC(C=2C(=CC3=CC=C(N=C3C=2)C=2SC=CC=2)Cl)=C2N1C=CN=C2N JSTPUNDUDLHYSG-UHFFFAOYSA-N 0.000 claims 1
- NSPUAURZKYEZAQ-UHFFFAOYSA-N 1-(6-chloro-2-thiophen-2-ylquinolin-7-yl)-3-cyclobutylimidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CCC2)=NC=1C(C(=CC1=CC=2)Cl)=CC1=NC=2C1=CC=CS1 NSPUAURZKYEZAQ-UHFFFAOYSA-N 0.000 claims 1
- LNENPGOMBMAEJP-UHFFFAOYSA-N 1-[4-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-3,6-dihydro-2h-pyridin-1-yl]ethanone Chemical compound C1N(C(=O)C)CCC(C=2N3C=CN=C(N)C3=C(C=3C=C4N=C(C=CC4=CC=3)C=3C=CC=CC=3)N=2)=C1 LNENPGOMBMAEJP-UHFFFAOYSA-N 0.000 claims 1
- BSPTWZDFLDXPKA-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C1N(C)CCC(C=2N3C=CN=C(N)C3=C(C=3C=C4N=C(C=CC4=CC=3)C=3C=CC=CC=3)N=2)=C1 BSPTWZDFLDXPKA-UHFFFAOYSA-N 0.000 claims 1
- RCWDNTWEIXTBTG-UHFFFAOYSA-N 3-(6-bicyclo[3.1.0]hexanyl)-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2C3CCCC32)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=C1 RCWDNTWEIXTBTG-UHFFFAOYSA-N 0.000 claims 1
- LLJPAIVIVLSZJV-UHFFFAOYSA-N 3-[3-(2-methoxyethoxy)cyclobutyl]-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C1C(OCCOC)CC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N LLJPAIVIVLSZJV-UHFFFAOYSA-N 0.000 claims 1
- DXKBLTMTTDDSQV-UHFFFAOYSA-N 3-[3-(2-methoxyethoxy)cyclobutyl]-1-(4-methyl-2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C1C(OCCOC)CC1C1=NC(C=2C=C3N=C(C=C(C)C3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N DXKBLTMTTDDSQV-UHFFFAOYSA-N 0.000 claims 1
- KTRLKEPQWZPLLL-UHFFFAOYSA-N 3-[3-(azetidin-1-ylmethyl)cyclobutyl]-1-(2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CC(CN3CCC3)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2OC1=CC=CC=C1 KTRLKEPQWZPLLL-UHFFFAOYSA-N 0.000 claims 1
- KCDLRDXYMVNZPG-UHFFFAOYSA-N 3-[3-(azetidin-1-ylmethyl)cyclobutyl]-1-(2-phenylquinazolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CC(CN3CCC3)C2)=NC=1C(C=C1N=2)=CC=C1C=NC=2C1=CC=CC=C1 KCDLRDXYMVNZPG-UHFFFAOYSA-N 0.000 claims 1
- IYTNOAIKJAKOBQ-UHFFFAOYSA-N 3-[3-(azetidin-1-ylmethyl)cyclobutyl]-1-(2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CC(CN3CCC3)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=N1 IYTNOAIKJAKOBQ-UHFFFAOYSA-N 0.000 claims 1
- BPQDPJNGZRONGX-UHFFFAOYSA-N 3-[3-(azetidin-1-ylmethyl)cyclobutyl]-1-(2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CC(CN3CCC3)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CS1 BPQDPJNGZRONGX-UHFFFAOYSA-N 0.000 claims 1
- SYJUORNLAUSPHR-UHFFFAOYSA-N 3-[3-(azetidin-1-ylmethyl)cyclobutyl]-1-(3-phenylquinoxalin-6-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CC(CN3CCC3)C2)=NC=1C(C=C1N=2)=CC=C1N=CC=2C1=CC=CC=C1 SYJUORNLAUSPHR-UHFFFAOYSA-N 0.000 claims 1
- ZHKAOBNTJHXVSR-UHFFFAOYSA-N 3-[3-(azetidin-1-ylmethyl)cyclobutyl]-1-(4-methyl-2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound N=1C2=CC(C3=C4C(N)=NC=CN4C(C4CC(CN5CCC5)C4)=N3)=CC=C2C(C)=CC=1OC1=CC=CC=C1 ZHKAOBNTJHXVSR-UHFFFAOYSA-N 0.000 claims 1
- FXRPEGTVXBMEDQ-UHFFFAOYSA-N 3-[3-(azetidin-1-ylmethyl)cyclobutyl]-1-(4-methyl-2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=1C=C2C(C)=CC(C=3C=CC=CC=3)=NC2=CC=1C(=C1C(N)=NC=CN11)N=C1C(C1)CC1CN1CCC1 FXRPEGTVXBMEDQ-UHFFFAOYSA-N 0.000 claims 1
- BLKIKWVZRFFMSI-UHFFFAOYSA-N 3-[3-(azetidin-1-ylmethyl)cyclobutyl]-1-(4-methyl-2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=1C=C2C(C)=CC(C=3N=CC=CC=3)=NC2=CC=1C(=C1C(N)=NC=CN11)N=C1C(C1)CC1CN1CCC1 BLKIKWVZRFFMSI-UHFFFAOYSA-N 0.000 claims 1
- ZXSMEAMNZCPABU-UHFFFAOYSA-N 3-[3-(azetidin-1-ylmethyl)cyclobutyl]-1-(4-methyl-2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=1C=C2C(C)=CC(C=3SC=CC=3)=NC2=CC=1C(=C1C(N)=NC=CN11)N=C1C(C1)CC1CN1CCC1 ZXSMEAMNZCPABU-UHFFFAOYSA-N 0.000 claims 1
- WNZJXGHVWGHWBZ-UHFFFAOYSA-N 3-[3-(azetidin-1-ylmethyl)cyclobutyl]-1-(6-chloro-2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CC(CN3CCC3)C2)=NC=1C(C(=CC1=CC=2)Cl)=CC1=NC=2OC1=CC=CC=C1 WNZJXGHVWGHWBZ-UHFFFAOYSA-N 0.000 claims 1
- HAFVYVTYISTQCA-UHFFFAOYSA-N 3-[3-(azetidin-1-ylmethyl)cyclobutyl]-1-(6-chloro-2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CC(CN3CCC3)C2)=NC=1C(C(=CC1=CC=2)Cl)=CC1=NC=2C1=CC=CC=C1 HAFVYVTYISTQCA-UHFFFAOYSA-N 0.000 claims 1
- BBUMOKGWHZSDSV-UHFFFAOYSA-N 3-[3-(azetidin-1-ylmethyl)cyclobutyl]-1-(6-chloro-2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CC(CN3CCC3)C2)=NC=1C(C(=CC1=CC=2)Cl)=CC1=NC=2C1=CC=CC=N1 BBUMOKGWHZSDSV-UHFFFAOYSA-N 0.000 claims 1
- IGQGOZJQNANYAA-UHFFFAOYSA-N 3-[3-(azetidin-1-ylmethyl)cyclobutyl]-1-(6-chloro-2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CC(CN3CCC3)C2)=NC=1C(C(=CC1=CC=2)Cl)=CC1=NC=2C1=CC=CS1 IGQGOZJQNANYAA-UHFFFAOYSA-N 0.000 claims 1
- AGAUBSNLJPHZHW-UHFFFAOYSA-N 3-[3-[(dimethylamino)methyl]cyclobutyl]-1-(2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C1C(CN(C)C)CC1C1=NC(C=2C=C3N=C(OC=4C=CC=CC=4)C=CC3=CC=2)=C2N1C=CN=C2N AGAUBSNLJPHZHW-UHFFFAOYSA-N 0.000 claims 1
- FSYHSNLAYZLREB-UHFFFAOYSA-N 3-[3-[(dimethylamino)methyl]cyclobutyl]-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C1C(CN(C)C)CC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N FSYHSNLAYZLREB-UHFFFAOYSA-N 0.000 claims 1
- IURNCGNYCSSLFG-UHFFFAOYSA-N 3-[3-[(dimethylamino)methyl]cyclobutyl]-1-(2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C1C(CN(C)C)CC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2N=CC=CC=2)=C2N1C=CN=C2N IURNCGNYCSSLFG-UHFFFAOYSA-N 0.000 claims 1
- PTOFUBGVEVTDOA-UHFFFAOYSA-N 3-[3-[(dimethylamino)methyl]cyclobutyl]-1-(2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C1C(CN(C)C)CC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2SC=CC=2)=C2N1C=CN=C2N PTOFUBGVEVTDOA-UHFFFAOYSA-N 0.000 claims 1
- MLXBGVQCKOFVTE-UHFFFAOYSA-N 3-[3-[(dimethylamino)methyl]cyclobutyl]-1-(4-methyl-2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C1C(CN(C)C)CC1C1=NC(C=2C=C3N=C(OC=4C=CC=CC=4)C=C(C)C3=CC=2)=C2N1C=CN=C2N MLXBGVQCKOFVTE-UHFFFAOYSA-N 0.000 claims 1
- QAEFNWNIDUIYLU-UHFFFAOYSA-N 3-[3-[(dimethylamino)methyl]cyclobutyl]-1-(4-methyl-2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C1C(CN(C)C)CC1C1=NC(C=2C=C3N=C(C=C(C)C3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N QAEFNWNIDUIYLU-UHFFFAOYSA-N 0.000 claims 1
- UEPKBNLLPLXRBW-UHFFFAOYSA-N 3-[3-[(dimethylamino)methyl]cyclobutyl]-1-(4-methyl-2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C1C(CN(C)C)CC1C1=NC(C=2C=C3N=C(C=C(C)C3=CC=2)C=2N=CC=CC=2)=C2N1C=CN=C2N UEPKBNLLPLXRBW-UHFFFAOYSA-N 0.000 claims 1
- FLYYUFXEANIZJX-UHFFFAOYSA-N 3-[3-[(dimethylamino)methyl]cyclobutyl]-1-(4-methyl-2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C1C(CN(C)C)CC1C1=NC(C=2C=C3N=C(C=C(C)C3=CC=2)C=2SC=CC=2)=C2N1C=CN=C2N FLYYUFXEANIZJX-UHFFFAOYSA-N 0.000 claims 1
- SHDOYMJQFXSBEK-UHFFFAOYSA-N 3-[4-(aminomethyl)cyclohexyl]-1-(2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C1CC(CN)CCC1C1=NC(C=2C=C3N=C(OC=4C=CC=CC=4)C=CC3=CC=2)=C2N1C=CN=C2N SHDOYMJQFXSBEK-UHFFFAOYSA-N 0.000 claims 1
- HNQYDDOYPIVAHP-UHFFFAOYSA-N 3-[4-(aminomethyl)cyclohexyl]-1-(2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C1CC(CN)CCC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2N=CC=CC=2)=C2N1C=CN=C2N HNQYDDOYPIVAHP-UHFFFAOYSA-N 0.000 claims 1
- HAZNXCGIXJLHAL-UHFFFAOYSA-N 3-[4-(aminomethyl)cyclohexyl]-1-(2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C1CC(CN)CCC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2SC=CC=2)=C2N1C=CN=C2N HAZNXCGIXJLHAL-UHFFFAOYSA-N 0.000 claims 1
- UWMZAZNVTCJAJI-UHFFFAOYSA-N 3-[4-amino-5-(2-phenoxyquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=NN2C(C2CC(O)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2OC1=CC=CC=C1 UWMZAZNVTCJAJI-UHFFFAOYSA-N 0.000 claims 1
- OTEYCFHTSSWJMC-UHFFFAOYSA-N 3-[4-amino-5-(2-phenylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=NN2C(C2CC(O)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=C1 OTEYCFHTSSWJMC-UHFFFAOYSA-N 0.000 claims 1
- CNHWBZDZZFOUCS-UHFFFAOYSA-N 3-[4-amino-5-(2-pyridin-2-ylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=NN2C(C2CC(O)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=N1 CNHWBZDZZFOUCS-UHFFFAOYSA-N 0.000 claims 1
- UMZJQOGWEHNJSW-UHFFFAOYSA-N 3-[4-amino-5-(2-thiophen-2-ylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=NN2C(C2CC(O)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CS1 UMZJQOGWEHNJSW-UHFFFAOYSA-N 0.000 claims 1
- ADRZODVEHFUUOO-UHFFFAOYSA-N 3-[4-amino-5-(6-chloro-2-phenylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=NN2C(C2CC(O)C2)=NC=1C(C(=CC1=CC=2)Cl)=CC1=NC=2C1=CC=CC=C1 ADRZODVEHFUUOO-UHFFFAOYSA-N 0.000 claims 1
- WUBQZGBUTBWZNI-UHFFFAOYSA-N 3-[8-amino-1-(2-anilino-6-chloroquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C(=CC1=CC=2)Cl)=CC1=NC=2NC1=CC=CC=C1 WUBQZGBUTBWZNI-UHFFFAOYSA-N 0.000 claims 1
- SIEHWDBFIIYBOG-UHFFFAOYSA-N 3-[8-amino-1-(2-anilino-8-fluoro-4-methylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound N=1C2=C(F)C(C3=C4C(N)=NC=CN4C(C4CC(O)C4)=N3)=CC=C2C(C)=CC=1NC1=CC=CC=C1 SIEHWDBFIIYBOG-UHFFFAOYSA-N 0.000 claims 1
- HORASWPXVYMFDE-UHFFFAOYSA-N 3-[8-amino-1-(2-anilino-8-fluoroquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C(=C1N=2)F)=CC=C1C=CC=2NC1=CC=CC=C1 HORASWPXVYMFDE-UHFFFAOYSA-N 0.000 claims 1
- KNNNVAYJYWJUJS-UHFFFAOYSA-N 3-[8-amino-1-(2-anilinoquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2NC1=CC=CC=C1 KNNNVAYJYWJUJS-UHFFFAOYSA-N 0.000 claims 1
- FTZQWHBTSPATPY-UHFFFAOYSA-N 3-[8-amino-1-(2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2OC1=CC=CC=C1 FTZQWHBTSPATPY-UHFFFAOYSA-N 0.000 claims 1
- PKCDDUHJAFVJJB-UHFFFAOYSA-N 3-[8-amino-1-(2-phenyl-7-quinolinyl)-3-imidazo[1,5-a]pyrazinyl]-1-methyl-1-cyclobutanol Chemical group C1C(C)(O)CC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N PKCDDUHJAFVJJB-UHFFFAOYSA-N 0.000 claims 1
- OEONHNQCPJBVRI-UHFFFAOYSA-N 3-[8-amino-1-(2-phenylquinazolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C=C1N=2)=CC=C1C=NC=2C1=CC=CC=C1 OEONHNQCPJBVRI-UHFFFAOYSA-N 0.000 claims 1
- XIGQKXNIOIKTTM-UHFFFAOYSA-N 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=C1 XIGQKXNIOIKTTM-UHFFFAOYSA-N 0.000 claims 1
- JXCXKCPTKOPYKT-UHFFFAOYSA-N 3-[8-amino-1-(2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=N1 JXCXKCPTKOPYKT-UHFFFAOYSA-N 0.000 claims 1
- SJIHLZCTWLBOEX-UHFFFAOYSA-N 3-[8-amino-1-(2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CS1 SJIHLZCTWLBOEX-UHFFFAOYSA-N 0.000 claims 1
- RFNLNDQYDHNDPK-UHFFFAOYSA-N 3-[8-amino-1-(3-phenylquinoxalin-6-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C=C1N=2)=CC=C1N=CC=2C1=CC=CC=C1 RFNLNDQYDHNDPK-UHFFFAOYSA-N 0.000 claims 1
- NGUMIDBSGGXFJK-UHFFFAOYSA-N 3-[8-amino-1-(6-chloro-2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C(=CC1=CC=2)Cl)=CC1=NC=2OC1=CC=CC=C1 NGUMIDBSGGXFJK-UHFFFAOYSA-N 0.000 claims 1
- VFMSUJWZZRHUCC-UHFFFAOYSA-N 3-[8-amino-1-(6-chloro-2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C(=CC1=CC=2)Cl)=CC1=NC=2C1=CC=CC=C1 VFMSUJWZZRHUCC-UHFFFAOYSA-N 0.000 claims 1
- GMWAJVNZYVRKSB-UHFFFAOYSA-N 3-[8-amino-1-(6-chloro-2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C(=CC1=CC=2)Cl)=CC1=NC=2C1=CC=CC=N1 GMWAJVNZYVRKSB-UHFFFAOYSA-N 0.000 claims 1
- WTNLZLHHVBFFSL-UHFFFAOYSA-N 3-[8-amino-1-(6-chloro-2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C(=CC1=CC=2)Cl)=CC1=NC=2C1=CC=CS1 WTNLZLHHVBFFSL-UHFFFAOYSA-N 0.000 claims 1
- NDRZZIJTNDXFKZ-UHFFFAOYSA-N 3-[8-amino-1-(8-fluoro-2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C(=C1N=2)F)=CC=C1C=CC=2OC1=CC=CC=C1 NDRZZIJTNDXFKZ-UHFFFAOYSA-N 0.000 claims 1
- VDDQUSUVKJGVCE-UHFFFAOYSA-N 3-[8-amino-1-(8-fluoro-2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C(=C1N=2)F)=CC=C1C=CC=2C1=CC=CC=C1 VDDQUSUVKJGVCE-UHFFFAOYSA-N 0.000 claims 1
- OIWSHRFQGPWBTG-UHFFFAOYSA-N 3-[8-amino-1-(8-fluoro-2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C(=C1N=2)F)=CC=C1C=CC=2C1=CC=CC=N1 OIWSHRFQGPWBTG-UHFFFAOYSA-N 0.000 claims 1
- XJOUBTVPJCMYSW-UHFFFAOYSA-N 3-[8-amino-1-(8-fluoro-2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=12C(N)=NC=CN2C(C2CC(O)C2)=NC=1C(C(=C1N=2)F)=CC=C1C=CC=2C1=CC=CS1 XJOUBTVPJCMYSW-UHFFFAOYSA-N 0.000 claims 1
- CLMNYETVRVPFNQ-UHFFFAOYSA-N 3-[8-amino-1-(8-fluoro-4-methyl-2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound N=1C2=C(F)C(C3=C4C(N)=NC=CN4C(C4CC(O)C4)=N3)=CC=C2C(C)=CC=1OC1=CC=CC=C1 CLMNYETVRVPFNQ-UHFFFAOYSA-N 0.000 claims 1
- JSFZRMQPAZXPJZ-UHFFFAOYSA-N 3-[8-amino-1-(8-fluoro-4-methyl-2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=1C=C2C(C)=CC(C=3C=CC=CC=3)=NC2=C(F)C=1C(=C1C(N)=NC=CN11)N=C1C1CC(O)C1 JSFZRMQPAZXPJZ-UHFFFAOYSA-N 0.000 claims 1
- ADFOUEFAROFAPA-UHFFFAOYSA-N 3-[8-amino-1-(8-fluoro-4-methyl-2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=1C=C2C(C)=CC(C=3N=CC=CC=3)=NC2=C(F)C=1C(=C1C(N)=NC=CN11)N=C1C1CC(O)C1 ADFOUEFAROFAPA-UHFFFAOYSA-N 0.000 claims 1
- FCCPCXYUVSJPMH-UHFFFAOYSA-N 3-[8-amino-1-(8-fluoro-4-methyl-2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclobutan-1-ol Chemical compound C=1C=C2C(C)=CC(C=3SC=CC=3)=NC2=C(F)C=1C(=C1C(N)=NC=CN11)N=C1C1CC(O)C1 FCCPCXYUVSJPMH-UHFFFAOYSA-N 0.000 claims 1
- KJEIFAVPAAICFH-UHFFFAOYSA-N 3-cyclobutyl-1-(2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CCC2)=NC=1C(C=C1N=2)=CC=C1C=CC=2OC1=CC=CC=C1 KJEIFAVPAAICFH-UHFFFAOYSA-N 0.000 claims 1
- PUECSCVGMXHNGF-UHFFFAOYSA-N 3-cyclobutyl-1-(2-phenylquinazolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CCC2)=NC=1C(C=C1N=2)=CC=C1C=NC=2C1=CC=CC=C1 PUECSCVGMXHNGF-UHFFFAOYSA-N 0.000 claims 1
- RXACVQGKQQDPHW-UHFFFAOYSA-N 3-cyclobutyl-1-(2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CCC2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=N1 RXACVQGKQQDPHW-UHFFFAOYSA-N 0.000 claims 1
- JXSPTGKBUMHKPS-UHFFFAOYSA-N 3-cyclobutyl-1-(2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CCC2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CS1 JXSPTGKBUMHKPS-UHFFFAOYSA-N 0.000 claims 1
- NUKKCOWHLBALKL-UHFFFAOYSA-N 3-cyclobutyl-1-(3-phenylquinoxalin-6-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CCC2)=NC=1C(C=C1N=2)=CC=C1N=CC=2C1=CC=CC=C1 NUKKCOWHLBALKL-UHFFFAOYSA-N 0.000 claims 1
- SWAGVZAHJHMQLK-UHFFFAOYSA-N 3-cyclobutyl-1-(4-methyl-2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound N=1C2=CC(C3=C4C(N)=NC=CN4C(C4CCC4)=N3)=CC=C2C(C)=CC=1OC1=CC=CC=C1 SWAGVZAHJHMQLK-UHFFFAOYSA-N 0.000 claims 1
- LIRPZEQFBMUJMU-UHFFFAOYSA-N 3-cyclobutyl-1-(4-methyl-2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=1C=C2C(C)=CC(C=3C=CC=CC=3)=NC2=CC=1C(=C1C(N)=NC=CN11)N=C1C1CCC1 LIRPZEQFBMUJMU-UHFFFAOYSA-N 0.000 claims 1
- IZVJYZOPJIDUMK-UHFFFAOYSA-N 3-cyclobutyl-1-(4-methyl-2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=1C=C2C(C)=CC(C=3N=CC=CC=3)=NC2=CC=1C(=C1C(N)=NC=CN11)N=C1C1CCC1 IZVJYZOPJIDUMK-UHFFFAOYSA-N 0.000 claims 1
- PTLUZEQPJCSGPX-UHFFFAOYSA-N 3-cyclobutyl-1-(4-methyl-2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=1C=C2C(C)=CC(C=3SC=CC=3)=NC2=CC=1C(=C1C(N)=NC=CN11)N=C1C1CCC1 PTLUZEQPJCSGPX-UHFFFAOYSA-N 0.000 claims 1
- VLLNXHBBDSGAMN-UHFFFAOYSA-N 3-cyclobutyl-1-(8-fluoro-2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CCC2)=NC=1C(C(=C1N=2)F)=CC=C1C=CC=2OC1=CC=CC=C1 VLLNXHBBDSGAMN-UHFFFAOYSA-N 0.000 claims 1
- FQDRXOZYCAIROH-UHFFFAOYSA-N 3-cyclobutyl-1-(8-fluoro-2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CCC2)=NC=1C(C(=C1N=2)F)=CC=C1C=CC=2C1=CC=CC=C1 FQDRXOZYCAIROH-UHFFFAOYSA-N 0.000 claims 1
- APIFMUCUEBBRIL-UHFFFAOYSA-N 3-cyclobutyl-1-(8-fluoro-2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CCC2)=NC=1C(C(=C1N=2)F)=CC=C1C=CC=2C1=CC=CC=N1 APIFMUCUEBBRIL-UHFFFAOYSA-N 0.000 claims 1
- GJKLYXYDODHWRE-UHFFFAOYSA-N 3-cyclobutyl-1-(8-fluoro-2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C2CCC2)=NC=1C(C(=C1N=2)F)=CC=C1C=CC=2C1=CC=CS1 GJKLYXYDODHWRE-UHFFFAOYSA-N 0.000 claims 1
- NMWVTYUICVVSGR-UHFFFAOYSA-N 3-tert-butyl-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine Chemical compound C=12C(N)=NC=CN2C(C(C)(C)C)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=C1 NMWVTYUICVVSGR-UHFFFAOYSA-N 0.000 claims 1
- XFAUYDLYCUJYSV-UHFFFAOYSA-N 4-[4-amino-5-(2-phenoxyquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-n-methylcyclohexane-1-carboxamide Chemical compound C1CC(C(=O)NC)CCC1C1=NC(C=2C=C3N=C(OC=4C=CC=CC=4)C=CC3=CC=2)=C2N1N=CN=C2N XFAUYDLYCUJYSV-UHFFFAOYSA-N 0.000 claims 1
- YDGDNXYPWGLIPJ-UHFFFAOYSA-N 4-[4-amino-5-(2-phenoxyquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxamide Chemical compound C1CC(C(=O)N)CCC1C1=NC(C=2C=C3N=C(OC=4C=CC=CC=4)C=CC3=CC=2)=C2N1N=CN=C2N YDGDNXYPWGLIPJ-UHFFFAOYSA-N 0.000 claims 1
- UAQXWZIQHXZCJM-UHFFFAOYSA-N 4-[4-amino-5-(2-phenylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-n-methylcyclohexane-1-carboxamide Chemical compound C1CC(C(=O)NC)CCC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1N=CN=C2N UAQXWZIQHXZCJM-UHFFFAOYSA-N 0.000 claims 1
- HBCAPMIAASQVJV-UHFFFAOYSA-N 4-[4-amino-5-(2-phenylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxamide Chemical compound C1CC(C(=O)N)CCC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1N=CN=C2N HBCAPMIAASQVJV-UHFFFAOYSA-N 0.000 claims 1
- VNZWYAYZHCVQBX-UHFFFAOYSA-N 4-[4-amino-5-(2-thiophen-2-ylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-n-methylcyclohexane-1-carboxamide Chemical compound C1CC(C(=O)NC)CCC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2SC=CC=2)=C2N1N=CN=C2N VNZWYAYZHCVQBX-UHFFFAOYSA-N 0.000 claims 1
- JFARFTCYNACBKC-UHFFFAOYSA-N 4-[4-amino-5-(2-thiophen-2-ylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxamide Chemical compound C1CC(C(=O)N)CCC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2SC=CC=2)=C2N1N=CN=C2N JFARFTCYNACBKC-UHFFFAOYSA-N 0.000 claims 1
- AFFAJKKEUPVOHZ-UHFFFAOYSA-N 4-[4-amino-5-(6-chloro-2-phenylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]-n-methylcyclohexane-1-carboxamide Chemical compound C1CC(C(=O)NC)CCC1C1=NC(C=2C(=CC3=CC=C(N=C3C=2)C=2C=CC=CC=2)Cl)=C2N1N=CN=C2N AFFAJKKEUPVOHZ-UHFFFAOYSA-N 0.000 claims 1
- ATRBOQYOTQQOKR-UHFFFAOYSA-N 4-[4-amino-5-(6-chloro-2-phenylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxamide Chemical compound C1CC(C(=O)N)CCC1C1=NC(C=2C(=CC3=CC=C(N=C3C=2)C=2C=CC=CC=2)Cl)=C2N1N=CN=C2N ATRBOQYOTQQOKR-UHFFFAOYSA-N 0.000 claims 1
- IFOXIBCMCRFTDR-UHFFFAOYSA-N 4-[8-amino-1-(2-anilino-4-methylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxamide Chemical compound N=1C2=CC(C3=C4C(N)=NC=CN4C(C4CCC(CC4)C(N)=O)=N3)=CC=C2C(C)=CC=1NC1=CC=CC=C1 IFOXIBCMCRFTDR-UHFFFAOYSA-N 0.000 claims 1
- NMFOYYHAHOOIGK-UHFFFAOYSA-N 4-[8-amino-1-(2-anilino-6-chloroquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxamide Chemical compound C1CC(C(=O)N)CCC1C1=NC(C=2C(=CC3=CC=C(NC=4C=CC=CC=4)N=C3C=2)Cl)=C2N1C=CN=C2N NMFOYYHAHOOIGK-UHFFFAOYSA-N 0.000 claims 1
- CCIFAKMVIOLFLI-UHFFFAOYSA-N 4-[8-amino-1-(2-anilinoquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-n-methylcyclohexane-1-carboxamide Chemical compound C1CC(C(=O)NC)CCC1C1=NC(C=2C=C3N=C(NC=4C=CC=CC=4)C=CC3=CC=2)=C2N1C=CN=C2N CCIFAKMVIOLFLI-UHFFFAOYSA-N 0.000 claims 1
- UEVWKCKEZWBGLQ-UHFFFAOYSA-N 4-[8-amino-1-(2-anilinoquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxamide Chemical compound C1CC(C(=O)N)CCC1C1=NC(C=2C=C3N=C(NC=4C=CC=CC=4)C=CC3=CC=2)=C2N1C=CN=C2N UEVWKCKEZWBGLQ-UHFFFAOYSA-N 0.000 claims 1
- NQOMKHOHRMJHBD-UHFFFAOYSA-N 4-[8-amino-1-(2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-n-methylcyclohexane-1-carboxamide Chemical compound C1CC(C(=O)NC)CCC1C1=NC(C=2C=C3N=C(OC=4C=CC=CC=4)C=CC3=CC=2)=C2N1C=CN=C2N NQOMKHOHRMJHBD-UHFFFAOYSA-N 0.000 claims 1
- IKEZNXIRHJNLCJ-UHFFFAOYSA-N 4-[8-amino-1-(2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxamide Chemical compound C1CC(C(=O)N)CCC1C1=NC(C=2C=C3N=C(OC=4C=CC=CC=4)C=CC3=CC=2)=C2N1C=CN=C2N IKEZNXIRHJNLCJ-UHFFFAOYSA-N 0.000 claims 1
- DLNKIGIQANOXSS-UHFFFAOYSA-N 4-[8-amino-1-(2-phenylquinazolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-n-methylcyclohexane-1-carboxamide Chemical compound C1CC(C(=O)NC)CCC1C1=NC(C=2C=C3N=C(N=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N DLNKIGIQANOXSS-UHFFFAOYSA-N 0.000 claims 1
- RXFZUDSOSLFURH-UHFFFAOYSA-N 4-[8-amino-1-(2-phenylquinazolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxamide Chemical compound C1CC(C(=O)N)CCC1C1=NC(C=2C=C3N=C(N=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N RXFZUDSOSLFURH-UHFFFAOYSA-N 0.000 claims 1
- RPFZLIBHERAFAC-UHFFFAOYSA-N 4-[8-amino-1-(2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-n-methylcyclohexane-1-carboxamide Chemical compound C1CC(C(=O)NC)CCC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2N=CC=CC=2)=C2N1C=CN=C2N RPFZLIBHERAFAC-UHFFFAOYSA-N 0.000 claims 1
- BQFDMPLUYBUGAG-UHFFFAOYSA-N 4-[8-amino-1-(2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxamide Chemical compound C1CC(C(=O)N)CCC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2N=CC=CC=2)=C2N1C=CN=C2N BQFDMPLUYBUGAG-UHFFFAOYSA-N 0.000 claims 1
- QBOULMQVLZHEDC-UHFFFAOYSA-N 4-[8-amino-1-(2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-n-methylcyclohexane-1-carboxamide Chemical compound C1CC(C(=O)NC)CCC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2SC=CC=2)=C2N1C=CN=C2N QBOULMQVLZHEDC-UHFFFAOYSA-N 0.000 claims 1
- SPMZWKKEDBCOQR-UHFFFAOYSA-N 4-[8-amino-1-(2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxamide Chemical compound C1CC(C(=O)N)CCC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2SC=CC=2)=C2N1C=CN=C2N SPMZWKKEDBCOQR-UHFFFAOYSA-N 0.000 claims 1
- FDFBIHCTUJYOCI-UHFFFAOYSA-N 4-[8-amino-1-(3-phenylquinoxalin-6-yl)imidazo[1,5-a]pyrazin-3-yl]-n-methylcyclohexane-1-carboxamide Chemical compound C1CC(C(=O)NC)CCC1C1=NC(C=2C=C3N=C(C=NC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N FDFBIHCTUJYOCI-UHFFFAOYSA-N 0.000 claims 1
- FZDZYEHWICMZFU-UHFFFAOYSA-N 4-[8-amino-1-(3-phenylquinoxalin-6-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxamide Chemical compound C1CC(C(=O)N)CCC1C1=NC(C=2C=C3N=C(C=NC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N FZDZYEHWICMZFU-UHFFFAOYSA-N 0.000 claims 1
- PXVOMQVYYHXHLJ-UHFFFAOYSA-N 4-[8-amino-1-(4-methyl-2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxamide Chemical compound N=1C2=CC(C3=C4C(N)=NC=CN4C(C4CCC(CC4)C(N)=O)=N3)=CC=C2C(C)=CC=1OC1=CC=CC=C1 PXVOMQVYYHXHLJ-UHFFFAOYSA-N 0.000 claims 1
- AHZOKLXKTHPNPB-UHFFFAOYSA-N 4-[8-amino-1-(4-methyl-2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxamide Chemical compound C=1C=C2C(C)=CC(C=3C=CC=CC=3)=NC2=CC=1C(=C1C(N)=NC=CN11)N=C1C1CCC(C(N)=O)CC1 AHZOKLXKTHPNPB-UHFFFAOYSA-N 0.000 claims 1
- LKNPNVKPDLLUTF-UHFFFAOYSA-N 4-[8-amino-1-(4-methyl-2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxamide Chemical compound C=1C=C2C(C)=CC(C=3N=CC=CC=3)=NC2=CC=1C(=C1C(N)=NC=CN11)N=C1C1CCC(C(N)=O)CC1 LKNPNVKPDLLUTF-UHFFFAOYSA-N 0.000 claims 1
- IQBWFTIHWGNIOU-UHFFFAOYSA-N 4-[8-amino-1-(4-methyl-2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxamide Chemical compound C=1C=C2C(C)=CC(C=3SC=CC=3)=NC2=CC=1C(=C1C(N)=NC=CN11)N=C1C1CCC(C(N)=O)CC1 IQBWFTIHWGNIOU-UHFFFAOYSA-N 0.000 claims 1
- DZTUYHSMVOTVGA-UHFFFAOYSA-N 4-[8-amino-1-(6-chloro-2-phenoxyquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxamide Chemical compound C1CC(C(=O)N)CCC1C1=NC(C=2C(=CC3=CC=C(OC=4C=CC=CC=4)N=C3C=2)Cl)=C2N1C=CN=C2N DZTUYHSMVOTVGA-UHFFFAOYSA-N 0.000 claims 1
- QFCNDYNHKFYORP-UHFFFAOYSA-N 4-[8-amino-1-(6-chloro-2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxamide Chemical compound C1CC(C(=O)N)CCC1C1=NC(C=2C(=CC3=CC=C(N=C3C=2)C=2C=CC=CC=2)Cl)=C2N1C=CN=C2N QFCNDYNHKFYORP-UHFFFAOYSA-N 0.000 claims 1
- CPOKTICLELXNBM-UHFFFAOYSA-N 4-[8-amino-1-(6-chloro-2-pyridin-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxamide Chemical compound C1CC(C(=O)N)CCC1C1=NC(C=2C(=CC3=CC=C(N=C3C=2)C=2N=CC=CC=2)Cl)=C2N1C=CN=C2N CPOKTICLELXNBM-UHFFFAOYSA-N 0.000 claims 1
- MCPRFDOHQWMHGP-UHFFFAOYSA-N 4-[8-amino-1-(6-chloro-2-thiophen-2-ylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexane-1-carboxamide Chemical compound C1CC(C(=O)N)CCC1C1=NC(C=2C(=CC3=CC=C(N=C3C=2)C=2SC=CC=2)Cl)=C2N1C=CN=C2N MCPRFDOHQWMHGP-UHFFFAOYSA-N 0.000 claims 1
- XMAINYAXXGANQO-UHFFFAOYSA-N 5-(6-chloro-2-phenylquinolin-7-yl)-7-cyclobutylimidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C=12C(N)=NC=NN2C(C2CCC2)=NC=1C(C(=CC1=CC=2)Cl)=CC1=NC=2C1=CC=CC=C1 XMAINYAXXGANQO-UHFFFAOYSA-N 0.000 claims 1
- WUOASISZRJYMGH-UHFFFAOYSA-N 5-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]pyrrolidin-3-ol Chemical compound C=12C(N)=NC=CN2C(C2NCC(O)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=C1 WUOASISZRJYMGH-UHFFFAOYSA-N 0.000 claims 1
- NKLZNCJPUYFHIY-UHFFFAOYSA-N 6-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]bicyclo[3.1.0]hexan-3-ol Chemical compound C=12C(N)=NC=CN2C(C2C3CC(O)CC32)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=C1 NKLZNCJPUYFHIY-UHFFFAOYSA-N 0.000 claims 1
- ZKGOZSFQTLJNBZ-UHFFFAOYSA-N 7-(8-amino-3-cyclobutylimidazo[1,5-a]pyrazin-1-yl)-4-n-methyl-2-n-phenylquinoline-2,4-diamine Chemical compound N=1C2=CC(C3=C4C(N)=NC=CN4C(C4CCC4)=N3)=CC=C2C(NC)=CC=1NC1=CC=CC=C1 ZKGOZSFQTLJNBZ-UHFFFAOYSA-N 0.000 claims 1
- KGRBADAKNUMRDQ-UHFFFAOYSA-N 7-[3-(azetidin-1-ylmethyl)cyclobutyl]-5-(2-phenoxyquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C=12C(N)=NC=NN2C(C2CC(CN3CCC3)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2OC1=CC=CC=C1 KGRBADAKNUMRDQ-UHFFFAOYSA-N 0.000 claims 1
- WJLGVZVFFAEDIQ-UHFFFAOYSA-N 7-[3-(azetidin-1-ylmethyl)cyclobutyl]-5-(2-phenylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C=12C(N)=NC=NN2C(C2CC(CN3CCC3)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=C1 WJLGVZVFFAEDIQ-UHFFFAOYSA-N 0.000 claims 1
- QAQGBAFHSRKCEY-UHFFFAOYSA-N 7-[3-(azetidin-1-ylmethyl)cyclobutyl]-5-(2-pyridin-2-ylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C=12C(N)=NC=NN2C(C2CC(CN3CCC3)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=N1 QAQGBAFHSRKCEY-UHFFFAOYSA-N 0.000 claims 1
- CXSVZPHFPGVBOJ-UHFFFAOYSA-N 7-[3-(azetidin-1-ylmethyl)cyclobutyl]-5-(2-thiophen-2-ylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C=12C(N)=NC=NN2C(C2CC(CN3CCC3)C2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CS1 CXSVZPHFPGVBOJ-UHFFFAOYSA-N 0.000 claims 1
- NFODFWQXWCQQPS-UHFFFAOYSA-N 7-[3-(azetidin-1-ylmethyl)cyclobutyl]-5-(6-chloro-2-phenylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C=12C(N)=NC=NN2C(C2CC(CN3CCC3)C2)=NC=1C(C(=CC1=CC=2)Cl)=CC1=NC=2C1=CC=CC=C1 NFODFWQXWCQQPS-UHFFFAOYSA-N 0.000 claims 1
- YBFYPQWYFAPKMO-UHFFFAOYSA-N 7-[3-[(dimethylamino)methyl]cyclobutyl]-5-(2-phenoxyquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C1C(CN(C)C)CC1C1=NC(C=2C=C3N=C(OC=4C=CC=CC=4)C=CC3=CC=2)=C2N1N=CN=C2N YBFYPQWYFAPKMO-UHFFFAOYSA-N 0.000 claims 1
- DUMREUSDZCTSTL-UHFFFAOYSA-N 7-[3-[(dimethylamino)methyl]cyclobutyl]-5-(2-phenylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C1C(CN(C)C)CC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1N=CN=C2N DUMREUSDZCTSTL-UHFFFAOYSA-N 0.000 claims 1
- QWPYLZMHPKANHI-UHFFFAOYSA-N 7-[3-[(dimethylamino)methyl]cyclobutyl]-5-(2-pyridin-2-ylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C1C(CN(C)C)CC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2N=CC=CC=2)=C2N1N=CN=C2N QWPYLZMHPKANHI-UHFFFAOYSA-N 0.000 claims 1
- CASABRSNEDOTGD-UHFFFAOYSA-N 7-[3-[(dimethylamino)methyl]cyclobutyl]-5-(2-thiophen-2-ylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C1C(CN(C)C)CC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2SC=CC=2)=C2N1N=CN=C2N CASABRSNEDOTGD-UHFFFAOYSA-N 0.000 claims 1
- LMXVBNRFZTXZPN-UHFFFAOYSA-N 7-[4-(aminomethyl)cyclohexyl]-5-(2-phenoxyquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C1CC(CN)CCC1C1=NC(C=2C=C3N=C(OC=4C=CC=CC=4)C=CC3=CC=2)=C2N1N=CN=C2N LMXVBNRFZTXZPN-UHFFFAOYSA-N 0.000 claims 1
- ZWGHOOKOAAAGIE-UHFFFAOYSA-N 7-[4-(aminomethyl)cyclohexyl]-5-(2-phenylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C1CC(CN)CCC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1N=CN=C2N ZWGHOOKOAAAGIE-UHFFFAOYSA-N 0.000 claims 1
- CEVCXSDTFRQXSN-UHFFFAOYSA-N 7-[4-(aminomethyl)cyclohexyl]-5-(2-thiophen-2-ylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C1CC(CN)CCC1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2SC=CC=2)=C2N1N=CN=C2N CEVCXSDTFRQXSN-UHFFFAOYSA-N 0.000 claims 1
- DAPALGNHEZQTBE-UHFFFAOYSA-N 7-[4-(aminomethyl)cyclohexyl]-5-(6-chloro-2-phenylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C1CC(CN)CCC1C1=NC(C=2C(=CC3=CC=C(N=C3C=2)C=2C=CC=CC=2)Cl)=C2N1N=CN=C2N DAPALGNHEZQTBE-UHFFFAOYSA-N 0.000 claims 1
- FVBDWDPDMYHKLF-UHFFFAOYSA-N 7-cyclobutyl-5-(2-phenoxyquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C=12C(N)=NC=NN2C(C2CCC2)=NC=1C(C=C1N=2)=CC=C1C=CC=2OC1=CC=CC=C1 FVBDWDPDMYHKLF-UHFFFAOYSA-N 0.000 claims 1
- BHTAGACZYNRXNC-UHFFFAOYSA-N 7-cyclobutyl-5-(2-phenylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C=12C(N)=NC=NN2C(C2CCC2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=C1 BHTAGACZYNRXNC-UHFFFAOYSA-N 0.000 claims 1
- XPZADZRJJNHSRH-UHFFFAOYSA-N 7-cyclobutyl-5-(2-pyridin-2-ylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C=12C(N)=NC=NN2C(C2CCC2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CC=N1 XPZADZRJJNHSRH-UHFFFAOYSA-N 0.000 claims 1
- ZDEINZBQIINEFR-UHFFFAOYSA-N 7-cyclobutyl-5-(2-thiophen-2-ylquinolin-7-yl)imidazo[5,1-f][1,2,4]triazin-4-amine Chemical compound C=12C(N)=NC=NN2C(C2CCC2)=NC=1C(C=C1N=2)=CC=C1C=CC=2C1=CC=CS1 ZDEINZBQIINEFR-UHFFFAOYSA-N 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 230000003844 B-cell-activation Effects 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000019878 Eales disease Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010052139 Eye oedema Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims 1
- 206010051151 Hyperviscosity syndrome Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010025538 Malignant ascites Diseases 0.000 claims 1
- 206010027295 Menometrorrhagia Diseases 0.000 claims 1
- 208000024599 Mooren ulcer Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 241000700639 Parapoxvirus Species 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000002151 Pleural effusion Diseases 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 208000027073 Stargardt disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 201000005485 Toxoplasmosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010053648 Vascular occlusion Diseases 0.000 claims 1
- 206010047663 Vitritis Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 201000009101 diabetic angiopathy Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 210000000416 exudates and transudate Anatomy 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 208000013653 hyalitis Diseases 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000013532 laser treatment Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000001491 myopia Diseases 0.000 claims 1
- 230000004379 myopia Effects 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000008798 osteoma Diseases 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 230000008054 signal transmission Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 208000001608 teratocarcinoma Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 208000021331 vascular occlusion disease Diseases 0.000 claims 1
- 230000008728 vascular permeability Effects 0.000 claims 1
- 201000009371 venous hemangioma Diseases 0.000 claims 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 1
- 102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 abstract 6
- 108091008646 testicular receptors Proteins 0.000 abstract 6
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55925004P | 2004-04-02 | 2004-04-02 | |
PCT/US2005/010606 WO2005097800A1 (en) | 2004-04-02 | 2005-03-31 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20090495T1 true HRP20090495T1 (hr) | 2009-10-31 |
Family
ID=34967819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20090495T HRP20090495T1 (hr) | 2004-04-02 | 2009-09-16 | Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom |
Country Status (30)
Country | Link |
---|---|
US (6) | US7534797B2 (zh) |
EP (4) | EP2168968B1 (zh) |
JP (2) | JP4832426B2 (zh) |
KR (1) | KR101079272B1 (zh) |
CN (2) | CN1960993A (zh) |
AP (1) | AP2139A (zh) |
AR (1) | AR048518A1 (zh) |
AT (1) | ATE433979T1 (zh) |
AU (1) | AU2005230818B2 (zh) |
BR (1) | BRPI0509576A (zh) |
CA (1) | CA2561950C (zh) |
CY (1) | CY1109372T1 (zh) |
DE (1) | DE602005014964D1 (zh) |
DK (1) | DK1740591T3 (zh) |
EA (1) | EA012873B1 (zh) |
ES (2) | ES2328833T3 (zh) |
HK (1) | HK1100040A1 (zh) |
HR (1) | HRP20090495T1 (zh) |
IL (1) | IL178419A0 (zh) |
MX (1) | MXPA06011423A (zh) |
MY (1) | MY143225A (zh) |
NO (1) | NO20064895L (zh) |
PL (2) | PL2168968T3 (zh) |
PT (2) | PT1740591E (zh) |
RU (1) | RU2379308C2 (zh) |
SG (1) | SG163576A1 (zh) |
SI (1) | SI1740591T1 (zh) |
TW (2) | TW201134828A (zh) |
UA (1) | UA89493C2 (zh) |
WO (1) | WO2005097800A1 (zh) |
Families Citing this family (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7429596B2 (en) * | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
AU2004282219C1 (en) * | 2003-10-15 | 2009-12-17 | Osi Pharmaceuticals, Inc. | Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors |
EP2168968B1 (en) | 2004-04-02 | 2017-08-23 | OSI Pharmaceuticals, LLC | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
MY139689A (en) * | 2004-07-20 | 2009-10-30 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
JP2008520744A (ja) * | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
KR20080078668A (ko) * | 2005-11-17 | 2008-08-27 | 오에스아이 파마슈티컬스, 인코포레이티드 | 융합된 바이사이클릭 mTOR 억제자 |
AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
TW200730529A (en) * | 2005-12-07 | 2007-08-16 | Osi Pharm Inc | Process to prepare substituted imidazopyrazine compounds |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
EP1979002A2 (en) * | 2005-12-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
TW200801008A (en) * | 2005-12-29 | 2008-01-01 | Abbott Lab | Protein kinase inhibitors |
CN101003537A (zh) * | 2006-01-17 | 2007-07-25 | 上海恒瑞医药有限公司 | 吡咯并哒嗪类衍生物及其制备方法和用途 |
US7659274B2 (en) * | 2006-01-25 | 2010-02-09 | Osi Pharmaceuticals, Inc. | Unsaturated mTOR inhibitors |
MX2008012929A (es) | 2006-04-04 | 2008-12-17 | Univ California | Antagonistas de cinasa. |
DE102006016426A1 (de) * | 2006-04-07 | 2007-10-11 | Merck Patent Gmbh | Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren |
EP2021338A1 (en) | 2006-05-09 | 2009-02-11 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
WO2008021781A1 (en) | 2006-08-07 | 2008-02-21 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
DE102006043443A1 (de) * | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
AU2007323725B2 (en) | 2006-11-22 | 2014-02-20 | Incyte Holdings Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
WO2008076143A1 (en) * | 2006-12-18 | 2008-06-26 | Osi Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
TW200900070A (en) * | 2007-02-27 | 2009-01-01 | Osi Pharm Inc | Combination cancer therapy |
US8124759B2 (en) | 2007-05-09 | 2012-02-28 | Abbott Laboratories | Inhibitors of protein kinases |
ES2372559T3 (es) * | 2007-05-09 | 2012-01-23 | Abbott Laboratories | Compuestos heterocíclicos condensados como inhibidores de proteína quinasas. |
WO2008141140A1 (en) * | 2007-05-09 | 2008-11-20 | Abbott Laboratories | Condensed heterocyclic compounds as inhibitors of protein kinases |
WO2009008992A2 (en) * | 2007-07-06 | 2009-01-15 | Osi Pharmaceuticals Inc. | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 |
EP2173338A1 (en) * | 2007-07-06 | 2010-04-14 | OSI Pharmaceuticals, Inc. | Combination anti-cancer therapy |
WO2009045361A2 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
CA2694356A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
SG187425A1 (en) | 2008-01-04 | 2013-02-28 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
EP2250173A1 (en) * | 2008-01-18 | 2010-11-17 | OSI Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン, エルエルシー | キナーゼ阻害剤および使用方法 |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
BRPI0910232A2 (pt) * | 2008-03-19 | 2015-09-29 | Osi Pharm Inc | formas de sais inibidores do mtor |
JP2011520970A (ja) * | 2008-05-19 | 2011-07-21 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換されたイミダゾピラジン類およびイミダゾトリアジン類 |
HUE034716T2 (hu) | 2008-05-21 | 2018-02-28 | Incyte Holdings Corp | 2-Fluor-N-metil-4-[7-(kinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamid sói és eljárások ezek elõállítására |
EP2313102A2 (en) * | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
WO2010006072A2 (en) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
JP5788316B2 (ja) | 2008-07-08 | 2015-09-30 | インテリカイン, エルエルシー | キナーゼインヒビターおよび使用方法 |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
CA2740885C (en) | 2008-10-16 | 2018-04-03 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8163509B2 (en) * | 2008-10-20 | 2012-04-24 | The Regents Of The University Of Colorado, A Body Corporate | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
JP2012518657A (ja) * | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 併用抗癌治療 |
JP2012519170A (ja) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法 |
WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2408479A1 (en) | 2009-03-18 | 2012-01-25 | OSI Pharmaceuticals, LLC | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
CA2752826A1 (en) * | 2009-04-20 | 2010-10-28 | OSI Pharmaceuticals, LLC | Preparation of c-pyrazine-methylamines |
EP2427192A1 (en) * | 2009-05-07 | 2012-03-14 | OSI Pharmaceuticals, LLC | Use of osi-906 for treating adrenocortical carcinoma |
WO2010129816A2 (en) | 2009-05-07 | 2010-11-11 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
NZ598220A (en) | 2009-08-17 | 2014-02-28 | Intellikine Llc | Heterocyclic compounds and uses thereof |
JP2013504543A (ja) | 2009-09-10 | 2013-02-07 | ノバルティス アーゲー | 二環ヘテロアリール類のエーテル誘導体 |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
US20120220595A1 (en) | 2009-11-12 | 2012-08-30 | OSI Pharmaceuticals, LLC | Deuterated Tyrosine Kinase Inhibitors |
CN102712648A (zh) | 2009-11-25 | 2012-10-03 | 诺瓦提斯公司 | 双环杂芳基的与苯稠合的6元含氧杂环衍生物 |
WO2011083391A2 (en) | 2010-01-05 | 2011-07-14 | Pfizer Inc. | Biomarkers for anti-igf-ir cancer therapy |
US9765037B2 (en) | 2010-01-28 | 2017-09-19 | University Of Washington Through Its Center For Commercialization | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases |
CN102812027B (zh) | 2010-02-03 | 2015-01-07 | 因西特公司 | 作为C-MET抑制剂的咪唑并[1,2-b][1,2,4]三嗪 |
WO2011100270A2 (en) | 2010-02-09 | 2011-08-18 | OSI Pharmaceuticals, LLC | Pet imaging |
WO2011109584A2 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20110275644A1 (en) | 2010-03-03 | 2011-11-10 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2544672A1 (en) | 2010-03-09 | 2013-01-16 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
CA2799579A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
WO2011157793A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
WO2011157787A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
US20130158264A1 (en) * | 2010-06-23 | 2013-06-20 | Arlindo L. Castelhano | Polymorphs of OSI-906 |
US20130123501A1 (en) * | 2010-07-30 | 2013-05-16 | Arlindo L. Castelhano | Process for the preparation of the compound osi-906 |
CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
ES2637113T3 (es) | 2011-01-10 | 2017-10-10 | Infinity Pharmaceuticals, Inc. | Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas |
AU2012212075A1 (en) | 2011-02-02 | 2013-07-18 | Amgen Inc. | Methods and compositons relating to inhibition of IGF-1R |
WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
SG192576A1 (en) | 2011-02-23 | 2013-09-30 | Pfizer | IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
EP2683722A1 (en) | 2011-03-08 | 2014-01-15 | Novartis AG | Fluorophenyl bicyclic heteroaryl compounds |
US20120232277A1 (en) * | 2011-03-08 | 2012-09-13 | Abbott Laboratories | Process for the preparation of 1,2,4-oxadiazol-3-yl derivatives of carboxylic acid |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
US8471027B2 (en) | 2011-04-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Adamantyl compounds |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN106243113B (zh) | 2011-07-19 | 2018-12-18 | 默沙东有限责任公司 | 作为btk抑制剂的选择的咪唑并吡嗪类 |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
LT2734186T (lt) | 2011-07-22 | 2018-12-10 | Glaxosmithkline Llc | Kompozicija |
RU2014111823A (ru) | 2011-08-29 | 2015-10-10 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
JP6342805B2 (ja) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ[3,4−d]ピリミジンおよびその用途 |
US9700619B2 (en) | 2011-11-11 | 2017-07-11 | Duke University | Combination drug therapy for the treatment of solid tumors |
UY34484A (es) | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
WO2013087647A1 (en) | 2011-12-15 | 2013-06-20 | Bayer Intellectual Property Gmbh | Substituted benzothienyl - pyrrolotriazines and uses thereof in the treatment cancer |
ES2581065T3 (es) | 2012-02-23 | 2016-08-31 | Bayer Intellectual Property Gmbh | Benzotienil-pirrolotriazinas sustituidas y usos de las mismas |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
US9173872B2 (en) | 2012-08-24 | 2015-11-03 | Glaxosmithkline Llc | Pyrazolopyrimidine compounds |
CN104995192A (zh) * | 2012-09-26 | 2015-10-21 | 加利福尼亚大学董事会 | Ire1的调节 |
ES2632448T3 (es) | 2012-11-20 | 2017-09-13 | Glaxosmithkline Llc | Nuevos compuestos |
US9428512B2 (en) | 2012-11-20 | 2016-08-30 | Glaxosmithkline Llc | Compounds |
HUE13857477T2 (hu) | 2012-11-20 | 2018-05-28 | Glaxosmithkline Llc | Új vegyületek |
TW201441234A (zh) | 2013-01-23 | 2014-11-01 | Merck Sharp & Dohme | Btk抑制劑 |
WO2014113942A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
CN105209042B (zh) | 2013-03-22 | 2019-03-08 | 米伦纽姆医药公司 | 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合 |
CA2913035C (en) | 2013-05-20 | 2017-08-01 | University Of Washington Through Its Center For Commercialization | 5-aminopyrazole-4-carboxamide inhibitors of cdpk1 |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
WO2015058084A1 (en) * | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
US10328080B2 (en) | 2013-12-05 | 2019-06-25 | Acerta Pharma, B.V. | Therapeutic combination of PI3K inhibitor and a BTK inhibitor |
EP3082810B1 (en) | 2013-12-18 | 2018-09-26 | Merck Sharp & Dohme Corp. | Erk inhibitors |
WO2015095102A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2015095099A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Btk inhibitors |
US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
MX2016012021A (es) | 2014-03-19 | 2017-04-13 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US9949971B2 (en) | 2014-06-17 | 2018-04-24 | Acerta Pharma B.V. | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor |
HRP20211813T1 (hr) | 2014-08-11 | 2022-03-04 | Acerta Pharma B.V. | Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
PL3218378T3 (pl) * | 2014-11-14 | 2020-10-19 | Nerviano Medical Sciences S.R.L. | Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych |
WO2016106624A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Tertiary alcohol imidazopyrazine btk inhibitors |
WO2016106623A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
WO2016106628A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106629A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106626A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors |
EP3250290A4 (en) * | 2015-01-26 | 2018-07-11 | University of Washington | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases |
JO3627B1 (ar) * | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
CN108349978B (zh) | 2015-07-02 | 2021-07-23 | 安塞塔制药公司 | (S)-4-(8-氨基-3-(1-(丁-2-炔酰基)吡咯烷-2-基)咪唑并[1,5-a]吡嗪-1-基)-N-(吡啶-2-基)苯甲酰胺的固体形式和制剂 |
KR20180030913A (ko) * | 2015-07-30 | 2018-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 치환된 비시클릭 헤테로아릴 화합물 |
WO2017027883A1 (en) | 2015-08-13 | 2017-02-16 | San Diego State University Research Foundation | Atropisomerism for increased kinase inhibitor selectivity |
CN108137607B (zh) | 2015-08-26 | 2021-04-06 | 缆图药品公司 | 适用于治疗与ntrk相关的病症的化合物和组合物 |
EP3350183A1 (en) | 2015-09-14 | 2018-07-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
TWI733713B (zh) | 2015-11-19 | 2021-07-21 | 美商纜圖藥品公司 | 用於治療神經促進性酪氨酸受體激酶相關之異常的化合物與組成物 |
WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
AU2017281797A1 (en) | 2016-06-24 | 2019-01-24 | Infinity Pharmaceuticals, Inc. | Combination therapies |
JP2020506895A (ja) * | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | インドールアミン2,3−ジオキシゲナーゼおよび/またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 |
CN108658990B (zh) * | 2017-03-31 | 2021-03-23 | 南京科技职业学院 | 一类新型咪唑并[1,5-a]吡嗪类布鲁顿激酶抑制剂 |
KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
CN108003163B (zh) * | 2017-11-30 | 2020-11-24 | 武汉九州钰民医药科技有限公司 | 用作激酶抑制剂的吡唑并嘧啶类化合物及其应用 |
JP2021529765A (ja) | 2018-06-29 | 2021-11-04 | インサイト・コーポレイションIncyte Corporation | Axl/mer阻害剤の製剤 |
EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
EP3969442A4 (en) * | 2019-05-17 | 2023-08-02 | Kinnate Biopharma Inc. | FIBROBLAST GROWTH FACTOR RECEPTOR KINASE INHIBITORS |
WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US11862306B1 (en) | 2020-02-07 | 2024-01-02 | Cvs Pharmacy, Inc. | Customer health activity based system for secure communication and presentation of health information |
MX2022015410A (es) * | 2020-06-05 | 2023-03-13 | Kinnate Biopharma Inc | Inhibidores de las cinasas receptoras del factor de crecimiento de fibroblastos. |
US20230374015A1 (en) * | 2020-06-05 | 2023-11-23 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
CN113740539B (zh) * | 2021-08-11 | 2023-07-25 | 中元汇吉生物技术股份有限公司 | 一种测定特异性生长因子的试剂盒 |
CN114920745B (zh) * | 2022-03-28 | 2024-05-24 | 深圳海博为药业有限公司 | 一种咪唑并吡嗪类化合物及其作为igf1r抑制剂的应用 |
US11976074B1 (en) | 2023-06-20 | 2024-05-07 | Sling Therapeutics, Inc. | Crystalline salts of Linsitinib |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE791025A (fr) | 1971-11-19 | 1973-05-07 | Allen & Hanburys Ltd | Composes heterocycliques |
US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
CA2078214C (en) | 1990-04-02 | 1995-03-28 | Robert Lee Dow | Benzylphosphonic acid tyrosine kinase inhibitors |
US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
US5276028A (en) * | 1990-06-22 | 1994-01-04 | Nordisk A/S | Imidazoquinoxaline compounds |
US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
ES2108120T3 (es) | 1991-05-10 | 1997-12-16 | Rhone Poulenc Rorer Int | Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf. |
US6194439B1 (en) | 1991-05-29 | 2001-02-27 | Pfizer Inc. | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
JP2914407B2 (ja) | 1991-09-11 | 1999-06-28 | 富士電機株式会社 | 自動販売機 |
MX9304801A (es) | 1992-08-06 | 1997-06-28 | Warner Lambert Co | 2-toindoles (selenoidoles) disulfuros (seleniduros) relacinados, los cuales inhiben a las proteinas tirosina cinasas y los cuales tienen propiedades anti-tumorales. |
HUT71553A (en) | 1992-08-06 | 1995-12-28 | Warner Lambert Co | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
JPH07133280A (ja) | 1993-11-09 | 1995-05-23 | Takeda Chem Ind Ltd | セフェム化合物、その製造法および抗菌組成物 |
US20030108545A1 (en) | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
DK0682027T3 (da) * | 1994-05-03 | 1998-05-04 | Ciba Geigy Ag | Pyrrolopyrimidinderivater med antiproliferativ virkning |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
US6514971B1 (en) | 1996-03-15 | 2003-02-04 | Zeneca Limited | Cinnoline derivatives and use as medicine |
NZ332645A (en) | 1996-05-01 | 2000-07-28 | Lilly Co Eli | use of a bis-indolylmaleimide derivative for treating VEGF related diseases |
UA54427C2 (uk) | 1996-05-01 | 2003-03-17 | Елі Ліллі Енд Компані | Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту |
US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
US5932242A (en) | 1996-10-15 | 1999-08-03 | The Liposome Company, Inc. | Ether lipid-containing pharmaceutical compositions and therapeutic uses thereof |
US7863444B2 (en) * | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
ZA200007412B (en) | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
HUP0200355A3 (en) * | 1998-09-18 | 2004-07-28 | Abbott Gmbh & Co Kg | 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use |
BR9913887A (pt) | 1998-09-18 | 2001-10-23 | Basf Ag | Composto, e, métodos de inibir a atividade de proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
WO2000035455A1 (en) | 1998-12-15 | 2000-06-22 | Telik, Inc. | Heteroaryl-aryl ureas as igf-1 receptor antagonists |
JP4876239B2 (ja) * | 1999-01-11 | 2012-02-15 | プリンストン ユニバーシティー | 標的確認のための高親和性阻害剤およびその使用 |
HUP0201480A3 (en) | 1999-05-14 | 2009-03-30 | Imclone Systems Inc | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
BR0010482A (pt) | 1999-05-21 | 2002-04-23 | Bristol Myers Squibb Co | Inibidores pirrolotriazìnicos de cinases |
US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
ATE341341T1 (de) | 1999-08-12 | 2006-10-15 | Wyeth Corp | Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs |
GB9919558D0 (en) | 1999-08-18 | 1999-10-20 | Hoechst Schering Agrevo Gmbh | Fungicidal compounds |
US6137880A (en) * | 1999-08-27 | 2000-10-24 | Westell Technologies, Inc. | Passive splitter filter for digital subscriber line voice communication for complex impedance terminations |
US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
WO2001072751A1 (en) * | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
GB0008368D0 (en) | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
GB0017635D0 (en) | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
AU2002239486A1 (en) | 2000-12-08 | 2002-06-18 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
EP1349574A2 (en) | 2001-01-09 | 2003-10-08 | MERCK PATENT GmbH | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
CA2436487A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd. | Methods of inhibiting kinases |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
CN1514833A (zh) | 2001-03-28 | 2004-07-21 | ����˹�ж�-����˹˹������˾ | 新型酪氨酸激酶抑制剂 |
JP2004528368A (ja) | 2001-05-08 | 2004-09-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 抗egfr抗体と抗ホルモン剤を用いた組合せ療法 |
TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
SE0102168D0 (sv) | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
EP1463742A4 (en) | 2001-06-21 | 2006-05-10 | Ariad Pharma Inc | NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES |
US7057076B2 (en) * | 2001-07-13 | 2006-06-06 | University Of Connecticut | Bicyclic and tricyclic cannabinoids |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
MXPA04002243A (es) | 2001-09-19 | 2004-06-29 | Aventis Pharma Sa | Compuestos quimicos. |
GB0122560D0 (en) | 2001-09-19 | 2001-11-07 | Aventis Pharma Ltd | Chemical compounds |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
US20030175763A1 (en) | 2001-12-20 | 2003-09-18 | Degenhardt Yan Y. | Identification of an amplified gene and target for drug intervention |
AU2003205768A1 (en) | 2002-02-14 | 2003-09-04 | Dana-Farber Cancer Institute Inc. | Methods and compositions for treating hyperproliferative conditions |
US20050215564A1 (en) | 2002-02-14 | 2005-09-29 | Stiles Charles D | Methods and compositions for treating hyperproliferative conditions |
US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
EP1496909B1 (en) | 2002-04-16 | 2007-02-14 | AstraZeneca AB | Combination therapy for the treatment of cancer |
DE10230604A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
DE10230605A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
WO2004014368A1 (en) | 2002-08-12 | 2004-02-19 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
US20040209930A1 (en) | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
EP1422220A1 (en) | 2002-11-20 | 2004-05-26 | Bayer CropScience SA | Process for the preparation of 2-aminomethylpyridine derivative |
DE10254853A1 (de) | 2002-11-25 | 2004-06-03 | Basf Ag | Verbessertes Verfahren zur Herstellung von Cyclopentenonen |
UA80171C2 (en) * | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
US7186832B2 (en) * | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
AP2005003390A0 (en) | 2003-03-12 | 2005-09-30 | Pfizer Prod Inc | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives. |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
AU2004282219C1 (en) | 2003-10-15 | 2009-12-17 | Osi Pharmaceuticals, Inc. | Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors |
AR046639A1 (es) | 2003-11-21 | 2005-12-14 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti- igfr1 |
US7572914B2 (en) | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
EP2168968B1 (en) | 2004-04-02 | 2017-08-23 | OSI Pharmaceuticals, LLC | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
AU2005249206A1 (en) | 2004-06-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Treatment with cisplatin and an EGFR-inhibitor |
EP1768982A2 (en) | 2004-06-29 | 2007-04-04 | Amgen Inc. | Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity |
MY139689A (en) | 2004-07-20 | 2009-10-30 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
US7674907B2 (en) | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
WO2006033001A1 (en) | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
US20070149567A1 (en) | 2004-09-23 | 2007-06-28 | Pfizer Inc | Quinoline compounds |
DE202005016343U1 (de) | 2005-10-19 | 2007-02-22 | Weidmüller Interface GmbH & Co. KG | Elektrische Steckverbindung mit Schnellentriegelung |
KR20080078668A (ko) | 2005-11-17 | 2008-08-27 | 오에스아이 파마슈티컬스, 인코포레이티드 | 융합된 바이사이클릭 mTOR 억제자 |
AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
EP1979002A2 (en) | 2005-12-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
US8575164B2 (en) | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
TW200801008A (en) | 2005-12-29 | 2008-01-01 | Abbott Lab | Protein kinase inhibitors |
US7659274B2 (en) * | 2006-01-25 | 2010-02-09 | Osi Pharmaceuticals, Inc. | Unsaturated mTOR inhibitors |
WO2007106503A2 (en) | 2006-03-13 | 2007-09-20 | Osi Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
US7893058B2 (en) | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
AU2007267121A1 (en) * | 2006-05-31 | 2007-12-06 | Galapagos N.V. | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases |
EP2081435B1 (en) | 2006-09-22 | 2016-05-04 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
WO2008076143A1 (en) | 2006-12-18 | 2008-06-26 | Osi Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
TW200900070A (en) | 2007-02-27 | 2009-01-01 | Osi Pharm Inc | Combination cancer therapy |
EP2173338A1 (en) * | 2007-07-06 | 2010-04-14 | OSI Pharmaceuticals, Inc. | Combination anti-cancer therapy |
WO2009008992A2 (en) | 2007-07-06 | 2009-01-15 | Osi Pharmaceuticals Inc. | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 |
WO2009045361A2 (en) * | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2227254A2 (en) | 2007-11-28 | 2010-09-15 | OSI Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit |
EP2250173A1 (en) | 2008-01-18 | 2010-11-17 | OSI Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
JP2011520970A (ja) * | 2008-05-19 | 2011-07-21 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換されたイミダゾピラジン類およびイミダゾトリアジン類 |
EP2408479A1 (en) | 2009-03-18 | 2012-01-25 | OSI Pharmaceuticals, LLC | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
US8852590B2 (en) | 2009-04-16 | 2014-10-07 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
CA2752826A1 (en) | 2009-04-20 | 2010-10-28 | OSI Pharmaceuticals, LLC | Preparation of c-pyrazine-methylamines |
EP2427192A1 (en) * | 2009-05-07 | 2012-03-14 | OSI Pharmaceuticals, LLC | Use of osi-906 for treating adrenocortical carcinoma |
US20120220595A1 (en) | 2009-11-12 | 2012-08-30 | OSI Pharmaceuticals, LLC | Deuterated Tyrosine Kinase Inhibitors |
EP2544672A1 (en) | 2010-03-09 | 2013-01-16 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US20130158264A1 (en) | 2010-06-23 | 2013-06-20 | Arlindo L. Castelhano | Polymorphs of OSI-906 |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
-
2005
- 2005-03-31 EP EP09156987.1A patent/EP2168968B1/en active Active
- 2005-03-31 JP JP2007506493A patent/JP4832426B2/ja active Active
- 2005-03-31 DE DE602005014964T patent/DE602005014964D1/de active Active
- 2005-03-31 AU AU2005230818A patent/AU2005230818B2/en not_active Ceased
- 2005-03-31 UA UAA200611523A patent/UA89493C2/uk unknown
- 2005-03-31 EP EP05742128A patent/EP1740591B1/en active Active
- 2005-03-31 AT AT05742128T patent/ATE433979T1/de active
- 2005-03-31 PT PT05742128T patent/PT1740591E/pt unknown
- 2005-03-31 MY MYPI20051468A patent/MY143225A/en unknown
- 2005-03-31 CN CNA2005800179805A patent/CN1960993A/zh active Pending
- 2005-03-31 TW TW100123371A patent/TW201134828A/zh unknown
- 2005-03-31 CA CA2561950A patent/CA2561950C/en not_active Expired - Fee Related
- 2005-03-31 US US11/095,162 patent/US7534797B2/en active Active
- 2005-03-31 MX MXPA06011423A patent/MXPA06011423A/es active IP Right Grant
- 2005-03-31 EA EA200601850A patent/EA012873B1/ru not_active IP Right Cessation
- 2005-03-31 AP AP2006003795A patent/AP2139A/en active
- 2005-03-31 DK DK05742128T patent/DK1740591T3/da active
- 2005-03-31 PL PL09156987T patent/PL2168968T3/pl unknown
- 2005-03-31 SI SI200530783T patent/SI1740591T1/sl unknown
- 2005-03-31 CN CN201210370045.9A patent/CN102924458B/zh active Active
- 2005-03-31 RU RU2006138624/04A patent/RU2379308C2/ru not_active IP Right Cessation
- 2005-03-31 BR BRPI0509576-0A patent/BRPI0509576A/pt not_active IP Right Cessation
- 2005-03-31 ES ES05742128T patent/ES2328833T3/es active Active
- 2005-03-31 WO PCT/US2005/010606 patent/WO2005097800A1/en active Search and Examination
- 2005-03-31 SG SG201004876-7A patent/SG163576A1/en unknown
- 2005-03-31 EP EP10185075A patent/EP2305682A1/en not_active Withdrawn
- 2005-03-31 AR ARP050101277A patent/AR048518A1/es not_active Application Discontinuation
- 2005-03-31 ES ES09156987T patent/ES2652440T3/es active Active
- 2005-03-31 EP EP10185046A patent/EP2308879A1/en not_active Withdrawn
- 2005-03-31 PT PT91569871T patent/PT2168968T/pt unknown
- 2005-03-31 TW TW094110343A patent/TWI378934B/zh not_active IP Right Cessation
- 2005-03-31 PL PL05742128T patent/PL1740591T3/pl unknown
-
2006
- 2006-10-03 IL IL178419A patent/IL178419A0/en not_active IP Right Cessation
- 2006-10-26 NO NO20064895A patent/NO20064895L/no not_active Application Discontinuation
- 2006-10-30 KR KR1020067022653A patent/KR101079272B1/ko not_active IP Right Cessation
-
2007
- 2007-07-10 HK HK07107395.9A patent/HK1100040A1/xx not_active IP Right Cessation
-
2008
- 2008-10-03 US US12/244,947 patent/US7820662B2/en active Active
-
2009
- 2009-04-21 JP JP2009102856A patent/JP4330659B2/ja active Active
- 2009-08-12 US US12/540,047 patent/US8101613B2/en active Active
- 2009-09-16 HR HR20090495T patent/HRP20090495T1/hr unknown
- 2009-09-17 CY CY20091100959T patent/CY1109372T1/el unknown
-
2011
- 2011-12-01 US US13/308,694 patent/US8367826B2/en not_active Expired - Fee Related
-
2012
- 2012-04-13 US US13/446,629 patent/US8735405B2/en active Active
-
2013
- 2013-01-11 US US13/739,442 patent/US8653268B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20090495T1 (hr) | Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom | |
CA2542481A1 (en) | Imidazopyrazine tyrosine kinase inhibitors | |
JP2007531754A5 (zh) | ||
RU2007106068A (ru) | Имидазотриазины в качестве ингибиторов протеинкиназы | |
Karimi et al. | Wells–Dawson heteropolyacid supported on silica: a highly efficient catalyst for synthesis of 2, 4, 5-trisubstituted and 1, 2, 4, 5-tetrasubstituted imidazoles | |
ZA200102201B (en) | 4-aminopyrrolopyrimidines as kinase inhibitors. | |
Reddy et al. | PEG-SO3H catalyzed synthesis and cytotoxicity of α-aminophosphonates | |
Adcock et al. | Diversity oriented synthesis: substitution at C5 in unreactive pyrimidines by Claisen rearrangement and reactivity in nucleophilic substitution at C2 and C4 in pteridines and pyrido [2, 3-d] pyrimidines | |
JP2015514056A5 (zh) | ||
US20170037047A1 (en) | Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells | |
AU2002241138B2 (en) | Imidazo-pyrimidine derivatives as ligands for GABA receptors | |
RU2017135214A (ru) | Соединения замещенного пиразола, содержащего пиримидинил, их получение и применение | |
MX2007009234A (es) | Dicetoacidos con estructuras nucleo-base: inhibidores anti-replicacion del vih por inhibicion de la integrasa del vih. | |
IL271973B (en) | An improved process for the preparation of aminopyrimidine derivatives | |
RU2015107426A (ru) | Пирроло[2,3-в]пиразины в качестве ингибиторов syk | |
WO2008018881A1 (en) | 6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors | |
WO2009091939A1 (en) | Imidazopyrazinol derivatives for the treatment of cancers | |
Kharitonov et al. | Synthetic transformation of higher terpenoids 31. Synthesis of 1, 2, 3-triazolyl-containing furan labdanoids and studies of their cytotoxic activity | |
CA3092680A1 (en) | Process for preparing soluble guanylate cyclase stimulators | |
JPS61221178A (ja) | 3‐アリールウラシル化合物 | |
徐琴 | Pyridine Mediated Regioselective Cyclization of 5-Arylidene-1, 3-dimethylpyrimidine-2, 4, 6 (1H, 3H, 5H)-trione with Methyl Perfluoroalk-2-ynoates | |
AR127456A1 (es) | Sintesis de [1,2,3]triazol[4,5-d]pirimidinas | |
RU2001111034A (ru) | 4-аминопирролопиримидины в качестве ингибиторов киназ | |
JPWO2019243822A5 (zh) | ||
Navin Kumar Reddy et al. | Improved Synthesis of Antiviral Drug Valacyclovir Hydrochloride |